Imperial College London
Portrait Picture

DrAkaalKaur

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Research Coordinator
 
 
 
//

Contact

 

+44 (0)20 7594 5960akaal.kaur10 Website

 
 
//

Location

 

Room 322ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@inproceedings{Kaur:2019:10.1111/dme.16_13883,
author = {Kaur, A and Walkey, HC and Godsl, IF and Misra, S and Williams, AJK and Bingley, PJ and Dunger, DB and Oliver, NO and Johnston, DG},
doi = {10.1111/dme.16_13883},
pages = {67--67},
publisher = {WILEY},
title = {Predictors of c-peptide in Type 1 diabetes within the first 60 days of diagnosis: Routine laboratory data from the After Diabetes Diagnosis Research Support System (ADDRESS-2) cohort},
url = {http://dx.doi.org/10.1111/dme.16_13883},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - CPAPER
AB  - Aims: To describe the factors predicting cpeptide within 60 days of diagnosis, in a multiethnic, incident Type 1 diabetes cohort.Methods: ADDRESS2 recruits patients with clinicianassigned Type 1 diabetes within six months of diagnosis. Clinical, demographic and routine laboratory data are collected. Islet autoantibodies: glutamic acid decarboxylase (GADA), insulinomaassociated protein 2 (IA2A) and zinc transporter8 (ZnT8A) are measured in those opting to give a blood sample (52%). We analysed data collected between 01 September 2011 and 30 June 2017.Results: Of the 4,606 participants recruited, 341 (7.4%) had a random cpeptide measured in clinic within the first 60 days of diagnosis (80% within the first week of diagnosis). The median cpeptide was 0.23nmol/l (IQR 0.14–0.38nmol/l). Cpeptide was more likely to be lower if participants: were children (0.19 vs 0.26nmol/l, p = 0.01); presented with diabetic ketoacidosis (DKA) (0.19 vs 0.25nmol/l, p < 0.001); and autoantibody positive (0.23 vs 0.32nmol/l, p = 0.004). There were no significant differences in cpeptide with gender, ethnicity (White vs nonWhite), body mass index (BMI) or time from diagnosis to date of cpeptide measurement. On multiple linear regression of all significant variables (n = 179), autoantibody positivity (coeff. –0.014, p = 0.005) and presenting with DKA (coeff. −0.13, p = 0.002) were strong independent predictors of lower cpeptide. When excluding antibody status from the regression model (n = 333), presenting with DKA (coeff. −0.16, p = 0.02) remained the only significant independent predictor of lower cpeptide.Conclusion: Patients with Type 1 diabetes have lower cpeptide close to diagnosis if they present with DKA and they are autoantibody positive, irrespective of age.Acknowledgement: On behalf of the ADDRESS2 Management Committee, Patient Advocate Group and Investigators
AU  - Kaur,A
AU  - Walkey,HC
AU  - Godsl,IF
AU  - Misra,S
AU  - Williams,AJK
AU  - Bingley,PJ
AU  - Dunger,DB
AU  - Oliver,NO
AU  - Johnston,DG
DO  - 10.1111/dme.16_13883
EP  - 67
PB  - WILEY
PY  - 2019///
SN  - 0742-3071
SP  - 67
TI  - Predictors of c-peptide in Type 1 diabetes within the first 60 days of diagnosis: Routine laboratory data from the After Diabetes Diagnosis Research Support System (ADDRESS-2) cohort
UR  - http://dx.doi.org/10.1111/dme.16_13883
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000460421300161&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - https://onlinelibrary.wiley.com/doi/full/10.1111/dme.16_13883
UR  - http://hdl.handle.net/10044/1/83974
ER  -
Download